Newsletter

Disseminated on Behalf of: Algernon Pharmaceuticals Algernon sold its Ifenprodil research program in Q2 of this year to U.S. based Seyltx, Inc. for US$2 million and a 20% common share equity position Sub-psychedelic DMT has been shown to promote brain healing...

Is Drug Repurposing the new breakthrough for faster approval of Psychedelic-assisted treatments? In this TDR Psychedelic Exclusive, we speak with the CEO of Algernon Pharmaceuticals (CNSX: AGN) (OTC: AGNPF) Christopher Moreau who explains the company’s recent...

CEO Christopher J. Moreau provides an update on Algernon Pharmaceuticals Inc. announcement that its subsidiary Algernon NeuroScience (AGN Neuro) has added a new clinical research program for the treatment of Traumatic Brain Injury (TBI) with AP-188...

Algernon Pharmaceuticals CEO Christopher J. Moreau joined Steve Darling from Proactive to share news the Company’s subsidiary Algernon NeuroScience has announced it has completed the first dosing in its Phase 1 clinical study of an intravenous formulation of AP-188 or...

  “Drug Could Possibly Both Reduce Acute Damage of the Stroke” - How DMT Could be the Future of Stroke Treatment     Dr Rick Strassman, one of the most well-known researchers and authors on DMT, shares with SR Times his expert knowledge on using DMT as...